NEJM This Week — November 3, 2022
Featuring articles on the effect of psilocybin on treatment-resistant depression, brentuximab vedotin in pediatric Hodgkin’s lymphoma, early infusion of amino acids and neurodisability at 2 years, and the mRNA-1273 vaccine in children 6 months to 5 years of age; a review article on noninvasive respiratory support in acute respiratory failure; a Clinical Problem-Solving on a shear decline; and Perspective articles on whether it is burnout or depression, on pharmaceutical marketing revisited, and on the worst thing.
